Cite
Devillier R, Forcade E, Garnier A, et al. In-depth time-dependent analysis of the benefit of Allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2021;doi: 10.1182/bloodadvances.2021004435.
Devillier, R., Forcade, E., Garnier, A., Guenounou, S., Thepot, S., Guillerm, G., Ceballos, P., Hicheri, Y., Dumas, P. Y., Peterlin, P., Hunault-Berger, M. M., Bene, M. C. C., Bouvier, A., Chevallier, P., Blaise, D., Vey, N., Pigneux, A., Récher, C., & Huynh, A. (2021). In-depth time-dependent analysis of the benefit of Allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood advances, . https://doi.org/10.1182/bloodadvances.2021004435
Devillier, Raynier, et al. "In-depth time-dependent analysis of the benefit of Allo-HSCT for elderly patients with CR1 AML: a FILO study." Blood advances vol. (2021). doi: https://doi.org/10.1182/bloodadvances.2021004435
Devillier R, Forcade E, Garnier A, Guenounou S, Thepot S, Guillerm G, Ceballos P, Hicheri Y, Dumas PY, Peterlin P, Hunault-Berger MM, Bene MCC, Bouvier A, Chevallier P, Blaise D, Vey N, Pigneux A, Récher C, Huynh A. In-depth time-dependent analysis of the benefit of Allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Adv. 2021 Sep 15; doi: 10.1182/bloodadvances.2021004435. Epub 2021 Sep 15. PMID: 34525180.
Copy
Download .nbib